RFAI · RF Acquisition Corp II
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $39.90
Note written ·
Price against the kill line
13.9% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $39.90, on record since 11 November 2026. The shares are up 269.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $39.90, over the 11 November 2026 close of $38.00, which would show the shares leading the S&P 500 and prove the lag call wrong.
Research onlyNot in the portfolio.
Catalyst
The business · as of
RF Acquisition Corp II is a Cayman blank-check shell with no operating revenue. It is merging with Nanyang Biologics, a Singapore AI drug-discovery company; its trust cash funds the deal. It filed a net loss of $0.1 million for the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- On 12 November 2026 the company filed its 10-Q for the quarter to 30 September 2026, showing a net loss of $0.1 million; the Nanyang Biologics merger approved on 19 August 2026 had not closed.
- What follows for the company
- The shell reports cash and short-term investments of $0.0 million, no debt, equity of negative $5.8 million and operating cash flow of negative $0.6 million over four quarters.
- What follows for its customers, suppliers and competitors
- The9 (NCTY) said on 24 August 2026 that it expects to hold about 15% to 16% of the combined company, which would list on Nasdaq as "NYB" after closing.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 12 November 2026) the shares carry a market value of $121 million and trade at 391.4 times earnings; price to book is not meaningful and EV/sales is not available. That holds only if the merged business delivers earnings far above the $0.3 million filed over four quarters.
Key figures from the filings · Financials
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Net cash, cash less debt ($M)
- 0.0
- Price to earnings (×)
- 391.3
All filed numbers
What RF Acquisition Corp II reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: 0.3 | −0.1 |
| Diluted shares, change on a year (%) | Not reported |
| Operating cash flow ($M) | −0.6 |
| Capital spending ($M) | Not reported |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 0.0 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 0.0 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | −5.8 |
| Market value ($M) | 121 |
| Enterprise value, market value plus net debt ($M) no debt reported | 121 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | 391.3 |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 0.1% of shares outstanding sold short, 1.0 days of average trading to cover, −42.2% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $0 |
The thesis
RF Acquisition Corp II is a blank-check shell whose shares are more likely to lag the S&P 500 over three months. The price rests on a small public float after 98.95% preliminary redemptions, and only the closing report with final redemptions, due by the 15 February 2027 outside date, can confirm that scarcity. Shareholders approved the Nanyang Biologics merger on 19 August 2026, and no closing report had been filed as of the 12 November 2026 10-Q.
The shares closed at $34.34 on 13 November 2026. That is 53.0% below the 52-week intraday high of $73.00 on 21 August 2026 and just under the 50-day average of $34.58. The 200-day average is $18.72, and the three-month change is 269.6% from the $9.29 close of 17 August 2026.
The 10-Q for the quarter to 30 September 2026, filed 12 November 2026, shows a net loss of $0.1 million and negative equity of $5.8 million. It reports no revenue. The price therefore reflects float scarcity and attention, not a filed earnings base.
Bullish and bearish views on RF Acquisition Corp II
The bull case on RF Acquisition Corp II (RFAI), in brief: preliminary redemptions imply a very small float. The bear case: no closing has been reported.
Bull case
- Preliminary redemptions imply a very small float. The 8-K filed 20 August 2026 reported redemption requests covering 3,956,323 shares, or 98.95% of the 3,998,108 public shares left after the extension redemption. If the final figure holds near that level, few public shares would exist against bursts of retail attention.
- The merger vote passed decisively. The business-combination proposal won 6,765,584 votes for and 440,604 against on 19 August 2026 (8-K, Item 5.07). Closing and the Nasdaq listing under the reserved ticker "NYB" are the open items.
- A large holder expects to stay in. The9 (NCTY) said on 24 August 2026, per a StockTitan summary, that it expects to hold about 15% to 16% of the combined company, subject to customary closing conditions.
- Buyers return on spikes. The shares were halted on an upside circuit breaker on 26 October 2026 on volume of 106,752 shares, against average daily volume of 20,082 shares in MarketBeat's 1 October 2026 short interest update. The shares closed at $38.00 on 11 November 2026, up from $33.49 on 10 November 2026.
Bear case
- No closing has been reported. The merger approved on 19 August 2026 had not closed as of the 10-Q filed 12 November 2026, about twelve weeks later. The deadline runs to 15 February 2027 through up to six one-month extensions, each needing a $75,000 trust deposit.
- The redemption figure is preliminary. The 20 August 2026 8-K states that final redemptions and trust cash are not set until closing, and holders can withdraw requests. A materially lower final percentage would remove the scarcity argument.
- Spikes have faded within days. The 26 October 2026 halt left a close of $31.73 on 28 October 2026. The $38.00 close of 11 November 2026 gave way to $34.35 on 12 November 2026 and $34.34 on 13 November 2026.
- The shell's own financials are thin. The 10-Q to 30 September 2026 reports cash and short-term investments of $0.0 million, no debt and equity of negative $5.8 million, or negative $1.66 a share. The filed price-to-earnings ratio of 391.4 rests on net income of $0.3 million over four quarters. The amended Form F-4 shows unaudited pro forma combined revenue of US$43,132 and a net loss of US$8,192,164 for the six months ended 31 March 2026.
- Trust value sits far below the price. The trust paid about $11.13 per share to redeeming holders on 12 August 2026. The 13 November 2026 close of $34.34 is roughly three times that figure, so the price rests on expected scarcity and not on cash backing.
Price setup
Recent closes were $34.49 on 6 November 2026, $32.00 on 9 November 2026, $33.49 on 10 November 2026, $38.00 on 11 November 2026, $34.35 on 12 November 2026 and $34.34 on 13 November 2026. The shares have held between roughly $31 and $38 on a closing basis since early October.
The last close is marginally below the 50-day average of $34.58 and well above the 200-day average of $18.72. The 52-week closing low is $9.29 (17 August 2026), and the 52-week intraday high is $73.00 (21 August 2026).
The sample of RFAI spikes since August is too small to say what repeats for this shell.
Catalysts ahead
- ~15 November 2026 (est.): Next $75,000 monthly trust extension deposit if closing has not occurred. A further extension would show closing slipping toward the 15 February 2027 outside date.
- ~15 December 2026 (est.): Following $75,000 monthly trust extension deposit if closing has not occurred. Repeated deposits without a closing report would extend the wait for final redemptions.
- 15 February 2027: Outside date for the business combination under the amended trust agreement. No further extensions exist after this date, so the structure must close or liquidate; the closing report with final redemptions settles the scarcity case.
What would change the view
A daily close above $39.90, over the 11 November 2026 close of $38.00, which would show the shares leading the S&P 500 and prove the lag call wrong.
What it trades with
RFAI trades on its own filings and retail attention, not on its sector. Benzinga's 21 August 2026 and 24 August 2026 pre-market lists showed it among small-cap movers alongside unrelated names. Short interest was 11,647 shares, 0.5% of shares outstanding, per MarketBeat on 1 October 2026, so a short squeeze is not what moves it. MarketBeat lists only quantitative ratings from Weiss Ratings and Wall Street Zen, and no analyst price target on RFAI has been identified.
The evidence, claim by claim (8)
- Preliminary redemption requests covered 3,956,323 public shares, 98.95% of the 3,998,108 public shares remaining after the extension redemption. RF Acquisition Corp II Form 8-K filed 20 August 2026, Item 8.01 · as of
- Shareholders approved the business-combination proposal with 6,765,584 votes for and 440,604 against. RF Acquisition Corp II Form 8-K filed 20 August 2026, Item 5.07 · as of
- Net loss of $0.1 million in the quarter to 30 September 2026; cash and short-term investments $0.0 million, no debt, equity negative $5.8 million. RF Acquisition Corp II 10-Q filed 12 November 2026 · as of
- Extension redemptions covered 833,157 shares at about $11.13 per share, leaving about $44.52 million in trust and 3,998,108 shares outstanding. RF Acquisition Corp II Form 8-K filed 14 August 2026, Item 8.01 · as of
- The shares closed at $38.00 on 11 November 2026, $34.35 on 12 November 2026 and $34.34 on 13 November 2026. Split-adjusted daily closes · as of
- Shares were halted on an upside circuit breaker on 26 October 2026 on volume of 106,752 shares; the close on 28 October 2026 was $31.73. Benzinga headline 26 October 2026; MarketBeat 27 October 2026 · as of
- Unaudited pro forma combined revenue was US$43,132 and net loss US$8,192,164 for the six months ended 31 March 2026. NYB Holdings amended Form F-4 · as of
- The9 said it expects to hold about 15% to 16% of the combined company, subject to customary closing conditions. The9 release 24 August 2026, via StockTitan summary · as of
Sources
- RF Acquisition Corp II - Form 8-K · sec.gov
- Stock Titan ·
- TipRanks
Related · shared themes
RDAC
Rising Dragon Acquisition
Rising Dragon Acquisition Corp., a blank-check company with no operating business, is more likely to lag the S&P 500 over three months: its…
XHG
XChange TEC.INC
XChange TEC.INC's shares trade on an AI-expansion plan with no disclosed First Cycle terms or US spending detail, so they are more likely…
U
Unity Software
Unity Software's advertising turnaround and reported takeover interest make the shares modestly more likely than not to beat the S&P 500…
CVS
CVS Health
CVS Health is modestly more likely to beat the S&P 500 over three months: Aetna's costs improved and 2026 guidance rose, and the February…